Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

Such a head-to-head trial was conducted by GlaxoSmithKline to compare their tyrosine kinase inhibitor, pazopanib, to another tyrosine kinase inhibitor, sunitinib, in 1110 patients with metastatic ...

You might have targeted drugs to treat a neuroendocrine tumour (NET). These drugs include sunitinib and everolimus. You might have immunotherapy to treat lung neuroendocrine carcinoma (NEC). These ...

Five-year results from a trial examining Exelixis’ Cabometyx as a therapy for previously untreated advanced renal cell carcinoma (RCC) sustaining progression-free (PFS) and overall survival (OS ...

Reference #21 should have been “Geynisman DM, Faccone J, Zhang Y, et al. Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.